<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53794">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02092831</url>
  </required_header>
  <id_info>
    <org_study_id>GP29284</org_study_id>
    <nct_id>NCT02092831</nct_id>
  </id_info>
  <brief_title>A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers</brief_title>
  <official_title>A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF FORMULATION AND TABLET HARDNESS ON THE RELATIVE BIOAVAILABILITY OF PICTILISIB (GDC-0941) IN HEALTHY SUBJECTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1, open-label, randomized, 4-period crossover study is designed to de termine the
      relative bioavailability of GDC-0941 administered as a single dose o f the market image
      formulation at 3 different hardnesses (hardness 1, 2, and 3) and as a single dose of the
      Phase 2 formulation to healthy male and female volun teers. Participants will be randomly
      assigned to 4 possible treatment sequences, each comprising 4 periods (1 per formulation),
      and GDC-0941 will be administere d based on the assigned sequence. The study is expected to
      last 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of plasma GDC-0941</measure>
    <time_frame>25 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of GDC-0941</measure>
    <time_frame>25 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative bioavailability (Frel) according to the model independent approach</measure>
    <time_frame>25 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>25 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>25 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0941</intervention_name>
    <description>Single dose market image tablet of hardness 1</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0941</intervention_name>
    <description>Single dose market image tablet of hardness 2</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0941</intervention_name>
    <description>Single dose market image tablet of hardness 3</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0941</intervention_name>
    <description>Single dose Phase 2 tablet formulation</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female participants between 18 and 55 years of age, inclusive,

          -  Body mass index (BMI) between 18.5 to 32 kg/m2, inclusive,

          -  Healthy, as determined by no clinically significant findings from medical history,
             ECG, and vital signs, and who are able to swallow and tolerate a tethered Heidelberg
             pH Capsule and have gastric pH measurements taken

        Exclusion Criteria:

          -  Any medical condition or history of such condition that may, in the opinion of the
             investigator, contraindicate participation in this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
